Get to know our clinical trials
Randomized phase III clinical trial comparing JNJ-79635322 with teclistamab in patients with relapsed or refractory multiple myeloma after 1 to 3 prior lines of treatment, including an anti-CD38 antibody and lenalidomide (TRIlogy-5).
THE OBJECTIVE OF THIS STUDY IS TO COMPARE THE EFFECTS OF JNJ-79635322 WITH THOSE OF TECLISTAMAB. TECLISTAMAB IS ALREADY USED TO TREAT ADULTS WITH MULTIPLE MYELOMA.
Technical Summary
- RANDOMIZED PHASE III STUDY COMPARING JNJ-79635322 WITH TECLISTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER 1 TO 3 PRIOR LINES OF TREATMENT, INCLUDING AN ANTI-CD38 ANTIBODY AND LENALIDOMIDE (TRILOGY-5).
- Code EudraCT: 2025-523815-12
- Protocol number: 79635322MMY3002
- Promoter: Janssen Cilag SA
- Molecule/Drug: JNJ-79635322
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.